Sign in

PHIO on Nasdaq

Phio Pharmaceuticals Corp.

American pharmaceutical preparations company based in King Of Prussia2

In its 2026 annual report the company says: “Phio Pharmaceuticals Corp. is a clinical stage biopharmaceutical company whose proprietary INTASYL® small interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. We are developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.”4

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with JUPITER NEUROSCIENCES, INC., SKINVISIBLE, INC. or BIOADAPTIVES, INC., or pick any stock.

  • TickerPHIO on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersMarlborough, United States2
  • Incorporated inDE3
  • Business address411 Swedeland Road, Suite 23-1080, King Of Prussia, Pa 194063
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300KOGMLSPLDVHR522
  • StatusActive2
  • LEI statusIssued and current2
  • Registered addressc/o PARACORP INCORPORATED, 2140 S DUPONT HWY, 19934 Camden, United States2
  • Registered withDivision of Corporations, Department of State, 50355732

See how the biggest companies compare on our leaderboards

Phio Pharmaceuticals Corp. (“ Phio ,” “ we ,” “ our ” or the “ Company ”) is a clinical stage biopharmaceutical company whose proprietary INTASYL® small interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. We are developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems. We are committed to discovering and developing innovative cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment and a single reportable segment.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2020

-100.0%Revenue growth, 20205
-67.6%Return on equity6
0.02×Debt to equity7
-$8.8MFree cash flow7

Financial statements

Revenue5$0 in 2020
0$10.0K$20.0K$30.0K2019: $21.0K$21.0K20192020: $0$02020
Operating income57-$8.8M in 2020−2% since 2019
-$10.0M-$7.5M-$5.0M-$2.5M02019: -$9.0M-$9.0M20192020: -$8.8M-$8.8M2020−2%
Net income57-$8.8M in 2020−1% since 2019
-$10.0M-$7.5M-$5.0M-$2.5M02019: -$8.9M-$8.9M20192020: -$8.8M-$8.8M2020−1%

Every line of the income statement as filed: the last 2 fiscal years, latest first.10

Period ending2025-12-312024-12-31
Research and development$4.6M$3.6M
General and administrative$4.6M$3.7M
Total operating expenses$9.2M$7.4M
Operating loss-$9.2M-$7.4M
Interest income, net$520.0K$231.0K
Other income, net$2.0K$6.0K
Net loss-$8.7M-$7.2M
Basic and diluted (in dollars per share)-$1.45-$9.08
Basic and diluted (in shares)6.0M shares787.5K shares

Compare Phio Pharmaceuticals Corp. with another company

Corporate structure

Phio Pharmaceuticals Corp. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Phio Pharmaceuticals Corp.

  • CVI Investments, Inc. Filed SCHEDULE 13G/A on Phio Pharmaceuticals Corp., latest Feb 17, 2026 (4 filings since Dec 26, 2024)
  • INTRACOASTAL CAPITAL, LLC Filed SCHEDULE 13G/A on Phio Pharmaceuticals Corp., latest Feb 13, 2026 (8 filings since Feb 11, 2022)
  • Orca Capital AG Filed SCHEDULE 13G/A on Phio Pharmaceuticals Corp., latest Dec 11, 2025 (6 filings since Jan 23, 2025)
  • Empery Asset Management, LP Filed SC 13G/A on Phio Pharmaceuticals Corp., latest Jan 20, 2022
  • Phio Pharmaceuticals Corp. Marlborough, Massachusetts, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Phio Pharmaceuticals Corp. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Machinery and equipment$265.0K11 Dec 31, 2024$964.0K11 Dec 31, 2023−72.5%
Furniture and fixtures$8.0K11 Dec 31, 2024$70.0K11 Dec 31, 2023−88.6%
Leasehold improvements$011 Dec 31, 2024$46.0K11 Dec 31, 2023−100.0%
Property and equipment, before depreciation$239.0K10 Dec 31, 2025$308.0K10 Dec 31, 2024−22.4%
Accumulated depreciation$228.0K10 Dec 31, 2025$306.0K10 Dec 31, 2024−25.5%
Property and equipment, net$11.0K10 Dec 31, 2025$2.0K10 Dec 31, 2024+450.0%
Operating-lease assets (leased space)$011 Dec 31, 2024$33.0K11 Dec 31, 2023−100.0%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$21.0M10 Dec 31, 2025$5.4M10 Dec 31, 2024+290.8%

Properties, in its own words

We operate primarily as a remote business. We maintain a mailing address at 411 Swedeland Road, King of Prussia, Pennsylvania, where we have contracted with Life Sciences of Pennsylvania for access to shared office and working space during normal business hours. This arrangement is on a month-to-month basis and is cancellable at any time.

Item 2 of the 10-K filed Mar 5, 2026.4

Leadership

Who has led Phio Pharmaceuticals Corp., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Geert Cauwenbergh2013–2019
  2. Gerrit Dispersyn2019–2022
  3. Robert J. Bitterman2023–now

Chair

  1. Robert J. Bitterman2022–now

President

  1. Geert Cauwenbergh2013–2018
  2. Gerrit Dispersyn2019–2022
  3. Robert J. Bitterman2023–2024

Chief financial officer

  1. Robert M. Infarinato2024
  2. Lisa Cabott Carson2026–now

Chief operating officer

  1. Gerrit Dispersyn2019
201520202025
Board members and other officers (15)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorCurtis A. Lockshin, Ph.D. named Dec 19, 2023 to Nov 12, 202533
  • DirectorJonathan A. Freeman named Nov 23, 2022 to Nov 12, 202533

Former names

  • RXi Pharmaceuticals CorpOct 25, 2011 to Nov 14, 20183

Timeline

  1. Oct 13, 20268-K Other events34
  2. Sep 28, 20268-K Executive or director change; Shareholder vote35
  3. Sep 14, 20268-K Other events36
  4. Aug 6, 20268-K Results of operations37
  5. Jul 21, 20268-K Executive or director change; Other events38
  6. May 7, 20268-K Results of operations39
  7. Apr 8, 20268-K Entered a material agreement40
  8. Mar 30, 20268-K Other events41
  9. Mar 5, 20268-K Results of operations42
  10. Feb 18, 20268-K Executive or director change43
  11. Feb 10, 20268-K Other events44
  12. Jan 20, 20268-K Other events45
  13. Feb 22, 2023New chief executive Robert J. Bitterman becomes CEO12
  14. Mar 5, 2019New chief executive Gerrit Dispersyn becomes CEO13
  15. Mar 1, 2013New chief executive Geert Cauwenbergh becomes CEO14
  16. Sep 8, 2011Founded Phio Pharmaceuticals Corp. is founded2

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.44) a share, on Nov 13, 2025.46

When it reported results

  1. Aug 6, 2026Reported quarterly or annual results37
  2. May 7, 2026Reported quarterly or annual results39
  3. Mar 5, 2026Reported quarterly or annual results42
  4. Nov 13, 2025Reported quarterly or annual results47
  5. Aug 14, 2025Reported quarterly or annual results48
  6. May 15, 2025Reported quarterly or annual results49
  7. Mar 31, 2025Reported quarterly or annual results50
  8. Nov 14, 2024Reported quarterly or annual results51

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

299 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 85 major events, 84 insider forms, 19 large holders, 12 private raises, 78 other. The latest 20:

  1. Oct 13, 20268-K EDGAR
  2. Sep 30, 20264 EDGAR
  3. Sep 29, 20264 EDGAR
  4. Sep 29, 20264 EDGAR
  5. Sep 29, 20264 EDGAR
  6. Sep 28, 2026S-8 EDGAR
  7. Sep 28, 20268-K EDGAR
  8. Sep 25, 20264 EDGAR
  9. Sep 23, 20264 EDGAR
  10. Sep 16, 20264 EDGAR
  11. Sep 15, 20264 EDGAR
  12. Sep 15, 20264 EDGAR
  13. Sep 14, 20268-K EDGAR
  14. Aug 20, 20264 EDGAR
  15. Aug 19, 20264 EDGAR
  16. Aug 14, 2026ARS ANNUAL REPORT EDGAR
  17. Aug 14, 2026DEFA14A ADDITIONAL DEFINITIVE PROXY SOLICITING MATERIALS EDGAR
  18. Aug 14, 2026DEF 14A EDGAR
  19. Aug 6, 20268-K EDGAR
  20. Aug 6, 202610-Q EDGAR

The 299 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

32 open-market trades by officers, directors and large owners since October 2021: 32 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 29, 2026Plott Ronald ToddDirectorBuy5,000$1.04$5.2KForm 4
Sep 28, 2026Plott Ronald ToddDirectorBuy5,000$1.03$5.2KForm 4
Sep 24, 2026BRADFORD PATRICIA ADirectorBuy6,500$1.01$6.6KForm 4
Sep 22, 2026Bitterman Robert JChairman, Pres. & CEOBuy2,000$1.03$2.1KForm 4
Sep 15, 2026BRADFORD PATRICIA ADirectorBuy12,000$1.03$12.4KForm 4
Aug 19, 2026Plott Ronald ToddDirectorBuy15,000$1.14$17.1KForm 4
Aug 18, 2026Bitterman Robert JChairman, Pres. & CEOBuy10,000$1.06$10.6KForm 4
Jun 26, 2026Bitterman Robert JChairman, Pres. & CEOBuy10,000$0.99$9.9KForm 4
Dec 31, 2025Bitterman Robert JChairman, Pres. & CEOBuy5,000$1.03$5.2KForm 4
Dec 23, 2025Bitterman Robert JChairman, Pres. & CEOBuy5,000$1.02$5.1KForm 4
Nov 21, 2025Bitterman Robert JChairman, Pres. & CEOBuy5,000$1.14$5.7KForm 4
Nov 18, 2025Bitterman Robert JChairman, Pres. & CEOBuy5,000$1.27$6.3KForm 4
Jun 10, 2025Bitterman Robert JChairman, Pres. & CEOBuy2,000$2.42$4.8KForm 4
Jun 10, 2025Ferrara Robert LDirectorBuy2,500$2.42$6.0KForm 4
Jun 9, 2025Bitterman Robert JChairman, Pres. & CEOBuy1,500$2.75$4.1KForm 4
May 22, 2025Bitterman Robert JChairman, Pres. & CEOBuy1,200$1.78$2.1KForm 4
May 21, 2025Bitterman Robert JChairman, Pres. & CEOBuy3,000$1.77$5.3KForm 4
May 20, 2025Ferrara Robert LDirectorBuy2,500$1.82$4.5KForm 4
Jun 7, 2024Bitterman Robert JChairman, Pres. & CEOBuy1,000$0.74$740Form 4
Jun 6, 2024Bitterman Robert JChairman, Pres. & CEOBuy1,000$0.75$750Form 4

All 32 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Robert J. Bitterman$419.1K$1.2M56
2025Chief Financial Officer$188.1K$373.0K56
2025Former VicePresident and Chief Financial Officer$126.1K$226.7K56
2024President and Chief Executive Officer$342.6K$387.0K56
2024Former VicePresident and Chief Financial Officer$75.5K$105.2K56

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Nov 4, 2025Raised $1.4 million in a private offering of securities Form D: $25.9 million offered in all Form D
  2. Jul 28, 2025Raised $232,149 in a private offering of securities Form D: $5.1 million offered in all Form D
  3. Jan 17, 2025Raised $152,500 in a private offering of securities Form D: $3.7 million offered in all Form D
  4. Jan 15, 2025Raised $208,334 in a private offering of securities Form D: $5 million offered in all Form D
  5. Jan 14, 2025Raised $265,918 in a private offering of securities Form D: $6.4 million offered in all Form D
  6. Dec 24, 2024Raised $30,000 in a private offering of securities Form D: $480,000 offered in all Form D
  7. Dec 20, 2024Raised $54,649 in a private offering of securities Form D: $1.3 million offered in all Form D
  8. Jul 11, 2024Raised $136,322 in a private offering of securities Form D: $6.4 million offered in all Form D
  9. Dec 8, 2023Raised $532,563 in a private offering of securities Form D: $5.4 million offered in all Form D
  10. Jun 2, 2023Raised $3 million in a private offering of equity Form D: $10.9 million offered in all Form D
  11. Apr 20, 2023Raised $4 million in a private offering of securities Form D: 3 investors so far Form D
  12. Nov 16, 2022Raised $1,750 in a private offering of equity Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Jane Street Group, LLC117,755$120.7K0.0%−1,434
Geode Capital Management, LLC114,574$117.4K0.0%−32,680
Vanguard Capital Management LLC94,262$96.6K0.0%+14,409
Nomura Asset Management International Inc.50,000$51.0K0.0%New
Cetera Investment Advisers47,500$48.7K0.0%+2,500
Citadel Advisors LLC47,150$48.3K0.0%New
Vanguard Fiduciary Trust Co38,169$39.1K0.0%No change
Northern Trust Corp27,768$28.5K0.0%+4,010
Two Sigma Investments, LP21,501$22.0K0.0%−10,994
XTX Topco Ltd18,475$18.9K0.0%−6,393
Bridgeway Capital Management, LLC12,000$12.3K0.0%New
Citigroup Inc11,605$11.9K0.0%+10,580
Captrust Financial Advisors10,000$10.2K0.0%No change
Tower Research Capital LLC (TRC)6,206$6.4K0.0%−1,414
Morgan Stanley6,000$6.2K0.0%No change
UBS Group AG5,387$5.5K0.0%−21,600
Osaic Holdings, Inc.2,000$2.1K0.0%No change
Spire Wealth Management1,990$2.0K0.0%−10
SBI Securities Co., Ltd.1,247$1.3K0.0%+23
Barclays PLC231$2370.0%New
Assetmark, Inc110$1130.0%No change
Hrt Financial LP13,182$130.0%−21,550
Activest Wealth Management9$90.0%No change
Caitong International Asset Management Co., Ltd6$60.0%+3

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Phio Pharmaceuticals Corp. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARPhio Pharmaceuticals Corp.1
  • CIK0001533040
  • Employer ID (EIN)45-32159034
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address411 Swedeland Road, Suite 23-1080, King Of Prussia, PA 194061
  • Phone(508) 767-38611
  • Shares outstanding11,617,250 as of Aug 4, 20269
  • Public float$11.2M as of Jun 30, 20254
  • AuditorGRANT THORNTON LLP, Philadelphia, Pennsylvania PCAOB ID 248; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceOct 25, 20111
  • Filings892 in all: 4 (251), 8-K (193), 10-Q (44), 424B3 (34), CORRESP (34), EFFECT (28), SC 13G/A (28), UPLOAD (26)1
    All 45 form types

    SC 13G (23), DEFA14A (21), 3 (20), S-1 (20), S-1/A (20), D (17), DEF 14A (17), 424B5 (16), 10-K (14), S-8 (12), SCHEDULE 13G/A (9), PRE 14A (8), S-3 (7), SCHEDULE 13G (5), 4/A (4), 424B4 (4), ARS (4), CT ORDER (4), 10-Q/A (3), 3/A (3), 8-A12B (2), 8-K/A (2), CERTNAS (2), POS AM (2), S-1MEF (2), SC 13D (2), 10-K/A (1), 25-NSE (1), 424B2 (1), 8-A12G (1), D/A (1), FWP (1), POS EX (1), RW (1), S-3/A (1), SC 13D/A (1), SP 15D2 (1)

  • Latest filingsAnnual report (10-K) Mar 5, 2026
    Quarterly report (10-Q) Aug 6, 2026
    Proxy statement (DEF 14A) Aug 14, 2026
    Latest 8-K (8-K) Oct 13, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value, $0.0001 per sharePHIONasdaq

From the cover page of the 10-K filed Mar 5, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Phio Pharmaceuticals Corp. names in Item 1A of its 10-K filed Mar 5, 2026: 23 risks under these headings, as written.4

  • Risks Relating to Our Financial Condition
  • We will require substantial additional funds to complete our research and development activities.
  • We have a history of net losses, and we expect to continue to incur net losses for the foreseeable future and may not achieve or maintain profitability.
  • Future financing may be obtained through, and future development efforts may be paid for by, the issuance of debt or equity, which may have an adverse effect on our stockholders or may otherwise adversely affect our business.
  • Our ability to use net operating loss carryforwards and other tax benefits may be limited.
  • Risks Relating to Our Business and Industry
  • We are dependent on the success of our INTASYL technology, and our product candidates based on this platform, which is unproven and may never lead to approved and marketable products.
  • Our product candidates are in an early stage of development and we may fail, experience significant delays, never advance clinical development or not be successful in our efforts to identify or discover additional product candidates, which may materially and adversely impact our business.
  • If we experience delays or difficulties in identifying and enrolling patients in clinical trials, it may lead to delays in generating clinical data and the receipt of necessary regulatory approvals.
  • Topline data may not accurately reflect or may materially differ from the complete results of a clinical trial.
  • We rely upon third-parties to conduct our clinical trials and other studies for our product candidates, and if they do not successfully fulfill their obligations, the development of our product candidates may be materially impacted.
  • A number of different factors could prevent us from advancing into clinical development, obtaining regulatory approval, and ultimately commercializing our product candidates on a timely basis, or at all.
The other 13 risks
  • Disruptions at the FDA, including due to a reduction in the FDA’s workforce and/or inadequate funding for the FDA, could prevent the FDA from performing normal functions on which our business relies, which could negatively impact our business.
  • We are subject to significant competition and may not be able to compete successfully.
  • If we fail to attract, hire and retain qualified personnel, we may not be able to design, develop, market or sell our products or successfully manage our business.
  • We are subject to potential liabilities from clinical testing and future product liability claims.
  • We rely upon third parties for the manufacture of the clinical supply for our product candidates.
  • Our business and operations would suffer in the event of a cybersecurity incident.
  • Risks Relating to Our Intellectual Property
  • We may be involved in litigation to protect our patents and intellectual property rights and our ability to protect our patents and intellectual property rights is uncertain and may subject us to potential liabilities.
  • Third parties may claim that we infringe their patents, which may result in substantial liabilities and prevent us from pursuing the development of our product candidates.
  • We are dependent on the patents we own and the technologies we license, and if we fail to maintain our patents or lose the right to license such technologies, our ability to develop new products would be harmed.
  • Risks Relating to Our Securities
  • The price of our Common Stock has been and may continue to be volatile.
  • We may not be able to maintain compliance with the continued listing requirements of The Nasdaq Capital Market.
  • Our Board of Directors has the authority to issue shares of “blank check” preferred stock and the terms of the preferred stock may reduce the value of our Common Stock.
  • Provisions of our certificate of incorporation and bylaws and Delaware law might discourage, delay or prevent a change of control of the Company or changes in our management and, as a result, depress the trading price of our Common Stock.

Legal proceedings

From time to time, we may become a party to various legal proceedings and complaints arising in the ordinary course of business. To our knowledge, we are not currently a party to any actual or threatened material legal proceedings.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
    SEC EDGAROther events
  35. 35
  36. 36
    SEC EDGAROther events
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
    SEC EDGAROther events
  42. 42
  43. 43
  44. 44
    SEC EDGAROther events
  45. 45
    SEC EDGAROther events
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56